SMYD2, SET and MYND domain containing 2, 56950

N. diseases: 54; N. variants: 1
Disease: Tumor Progression ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.050 Biomarker phenotype BEFREE Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma. 31754403 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.050 Biomarker phenotype BEFREE In vivo and in vitro experiments were performed to explore the function of SMYD2 in cancer progression. 31548876 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.050 AlteredExpression phenotype BEFREE The protein lysine methyltransferase SMYD2 has recently emerged as a new enzyme modulate gene transcription or signaling pathways, and involved into tumor progression. 31106145 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.050 AlteredExpression phenotype BEFREE Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma. 30319138 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.050 Biomarker phenotype BEFREE These findings suggest that SMYD2 plays a role in tumor progression and might be a useful prognosticator in HPV-unrelated, nonmultiple HNSCC. 26826421 2016